A Comparison between the nephrotoxic profile of gentamicin and gentamicin nanoparticles in mice

Journal of Biochemical and Molecular Toxicology

Volumn 29, Issue 2, 2015, Pages 57-62

  Jamshidzadeh, Akram ^a,b   Heidari, Reza ^a   Mohammadi Samani, Soliman ^b   Azarpira, Negar ^c   Najbi, Asma ^a,b   Jahani, Parisa ^d   Abdoli, Narges ^e  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Aminoglycoside Antibiotic; Kidney Injury; Nano drug; Nephrotoxicity; Renal Failure

Indexed keywords

ALGINIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE; GENTAMICIN; NANOGENTAMICIN; NANOPARTICLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ANIMALIA; MUS; NEGIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CREATININE; GENTAMICINS; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MICE; NANOPARTICLES; UREA;

EID: 84922778362     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.21667     Document Type: Article

References (40)

1. Mingeot-Leclercq M-P, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-1012.
2. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011;41(6):441-449.
3. Luft FC, Bloch R, Sloan RS, Yum MN, Costello R, Maxwell DR. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978;138(4):541-545.
4. Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167(1):173-179.
5. Luft FC, Patel V, Yum MN, Patel B, Kleit SA. Experimental aminoglycoside nephrotoxicity. J Lab Clin Med 1975;86(2):213-220.
6. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79(1):33-45.
7. Wedeen RP, Batuman V, Cheeks C, Marquet E, Sobel H. Transport of gentamicin in rat proximal tubule. Lab Invest 1983;48(2):212-223.
8. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail 1999;21(3/4):433-442.
9. Yang C-L, Du X-H, Han Y-X. Renal cortical mitochondria are the source of oxygen free radicals enhanced by gentamicin. Ren Fail 1995;17(1):21-26.
10. Sandoval R, Leiser J, Molitoris BA. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J Am Soc Nephrol 1998;9(2):167-174.
11. Zorov DB. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney Int 2010;77(10):841-843.
12. Hostetler KY, Hall LB. Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci U S A 1982;79(5):1663-1667.
13. Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986;237(3):919-925.
14. Williams PD, Holohan PD, Ross CR. Gentamicin nephrotoxicity II. Plasma membrane changes. Toxicol Appl Pharmacol 1981;61(2):243-251.
15. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990;88(3):S16-S20.
16. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100(3):352-357.
17. Walker RJ, Duggin GG. Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 1988;28(1):331-345.
18. Barza M, Lauermann M. Why monitor serum levels of gentamicin? Clin Pharmacokinet 1978;3(3):202-215.
19. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86(3):215-223.
20. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70(1):1-20.
21. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008;60(15):1638-1649.
22. Eslami SH, Ebrahimzadeh MA, Moghaddam HA, Nabavi SF, Jafari N, Nabavi SM. Renoprotective effect of Eryngium caucasicum in gentamicin-induced nephrotoxic mice. Arch Biol Sci 2011;63(1):157-160.
23. Moezi L, Heidari R, Amirghofran Z, Nekooeian AA, Monabati A, Dehpour AR. Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: The role of nitric oxide and IL-1b. Pharmacol Rep 2013;65(134):134-143.
24. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Control Release 2007;119(1):5-24.
25. Josepovitz C, Pastoriza-Munoz E, Timmerman D, Scott M, Feldman S, Kaloyanides GJ. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J Pharmacol Exp Ther 1982;223(2):314-321.
26. Antoine DJ, Srivastava A, Pirmohamed M, Park BK. Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. Biochem Pharmacol 2010;79(4):647-654.
27. Kotnis MS, Patel P, Menon SN, Sane RT. Renoprotective effect of Hemidesmus indicus, a herbal drug used in gentamicin-induced renal toxicity. Nephrology 2004;9(3):142-152.
28. Pedraza-Chaverrí J, González-Orozco AE, Maldonado PD, Barrera D, Medina-Campos ON, Hernández-Pando R. Diallyl disulfide ameliorates gentamicin-induced oxidative stress and nephropathy in rats. Eur J Pharmacol 2003;473(1):71-78.
29. Nitha B, Janardhanan KK. Aqueous-ethanolic extract of morel mushroom mycelium, Morchella esculenta, protects cisplatin and gentamicin induced nephrotoxicity in mice. Food Chem Toxicol 2008;46(9):3193-3199.
30. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008;19(5):923-932.
31. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia K, Ehyaei N, Valizadeh H. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2011;88(1):39-44.
32. Azhdarzadeh M, Lotfipour F, Zakeri-Milani P, Mohammadi G, Valizadeh H. Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria. Adv Pharm Bull 2012;2(1):17-24.
33. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005;93(6):678-687.
34. Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012;109(28):11294-11299.
35. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 2001;13(5):461-472.
36. Kovács E, Savopol T, Iordache M-M, Săplăcan L, Sobaru I, Istrate C, Mingeot-Leclercq M-P, Moisescu M-G. Interaction of gentamicin polycation with model and cell membranes. Bioelectrochemistry 2012;87:230-235.
37. Nagai J, Komeda T, Yumoto R, Takano M. Effect of protamine on the accumulation of gentamicin in opossum kidney epithelial cells. J Pharm Pharmacol 2013;65(3):441-446.
38. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 1999;16(1):3-27.
39. Sundar S, Kundu J, Kundu SC. Biopolymeric nanoparticles. Sci Tech Adv Mat 2010;11(1):1-13.
40. Dornelles Cherobim M, Correa Amaral A, Campos Dias S, Luiz Franco O. Nanoformulated Antibiotics: the Next Step for Pathogenic Bacteria Control. Curr Med Chem 2013;20(10):1232-1240.